Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2017/0298130 SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with...
2017/0298129 Fc RECEPTOR-BINDING POLYPEPTIDES WITH MODIFIED EFFECTOR FUNCTIONS
Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A)...
2017/0298128 METHODS AND COMPOSITIONS FOR TREATING AGE-RELATED DISORDERS
The present invention relates to methods and compositions containing an antagonist of a negative regulator of GDF-11 (e.g., an antibody) for use in treating an...
2017/0298127 ANTI-PACAP ANTIBODIES AND USES THEREOF
The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding...
2017/0298126 METHODS OF TREATING INFLAMMATORY DISEASES
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic...
2017/0298125 ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF
This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize...
2017/0298124 ANTIBODIES AGAINST PATHOLOGICAL FORMS OF TDP-43 AND USES THEREOF
Disclosed herein are novel pathological form of TDP-43, monoclonal antibodies against such pathological form of TDP-43, and uses thereof. The novel...
2017/0298123 ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9...
2017/0298122 ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS
The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
2017/0298121 ANTI-SERUM ALBUMIN BINDING VARIANTS
The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates...
2017/0298120 ANTIBODIES THAT BIND EBOLA GLYCOPROTEIN AND USES THEREOF
Isolated monoclonal antibodies which bind to Ebola virus glycoprotein and related antibody-based compositions and molecules are disclosed. Also disclosed are...
2017/0298119 ANTIBODY MOLECULES TO ZIKA VIRUS AND USES THEREOF
Antibody molecules that specifically bind to Zika virus are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose Zika virus...
2017/0298118 METHODS FOR SCREENING ANTIBODIES
The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.
2017/0298117 USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting...
2017/0298116 Method for producing antigen-specific B cells and their use for the production of hybridoma cells and...
The invention refers to a non-therapeutic method for producing antigen-specific B cells by using the adoptive cell transfer of primed B cells, especially of...
2017/0298115 HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding...
2017/0298114 Loss of Function mutations in KCNJ10 cause SeSAME, a human syndrome with sensory, neurological, and renal deficits
The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a...
2017/0298113 SYNTHETIC SOMATOSTATIN RECEPTOR LIGANDS
Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic...
2017/0298112 PEPTIDE-OLIGOUREA FOLDAMER COMPOUNDS AND METHODS OF THEIR USE
The present description provides compositions and methods for producing therapeutic compounds. In another aspect the description provides methods for...
2017/0298111 HUMAN G PROTEIN ALPHA SUBUNIT Gai1 WITH AT LEAST ONE MUTATED AMINO ACID RESIDUE
The present application discloses in detail mutant ligands of the human G protein alpha-subunit--G.alpha.i1--, wherein at least one amino acid residue has been...
2017/0298110 DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF
In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a...
2017/0298109 TUMOR ANTIGEN PEPTIDE
The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that...
2017/0298108 COMPOSITIONS COMPRISING GRIM-19 THERAPEUTICS AND METHODS OF USE
The present invention provides nucleic acids encoding a fusion protein comprising a nucleotide sequence encoding GRIM-19 or a biologically active fragment or...
2017/0298107 USE OF A SMALL NATIVE PEPTIDE ACTIVATOR OF SERCA PUMP FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS...
The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of...
2017/0298105 Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist
Methods of using an ET.sub.B receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ET.sub.B receptor...
2017/0298104 CONOTOXIN POLYPEPTIDE K-CPTX-BT103, AND METHOD FOR PREPARATION THREOF AND APPLICATION THEREOF
Disclosed are a conotoxin polypeptide .kappa.-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the...
2017/0298103 CONOTOXIN POLYPEPTIDE K-CPTX-BT105, AND METHOD FOR PREPARATION THREOF AND APPLICATION THEREOF
Disclosed are a conotoxin polypeptide .kappa.-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the...
2017/0298102 Nutritive Proteins and Methods
Nutritive proteins are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues...
2017/0298101 PREFUSION RSV F PROTEINS AND THEIR USE
Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens...
2017/0298100 ANTI-VIRAL PEPTIDES
Novel antiviral polypeptides are disclosed along with methods for their use to interfere with viral replication cycles by substantially impairing the binding...
2017/0298099 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES
The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The...
2017/0298098 CONOTOXIN POLYPEPTIDE K-CPTX-BT104, AND METHOD FOR PREPARATION THREOF AND APPLICATION THEREOF
Disclosed are a conotoxin polypeptide .kappa.-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the...
2017/0298097 Peptide Derivatives and Uses Thereof
The invention provides for novel peptide derivatives and compositions comprising the same. The invention further provides methods of treatment comprising...
2017/0298096 IMMUNE SYSTEM MODULATORS
The present invention described herein relates to the composition that interact with molecules that suppress the immune system. More specifically, embodiments...
2017/0298095 TREATMENT OF IL-17 MEDIATED DISEASE BY BLOCKING SEFIR-SEFIR INTERACTIONS
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy...
2017/0298094 Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof
This application describes a family of compounds acting as .beta.-arrestin effectors. Such compounds may provide significant therapeutic benefit in the...
2017/0298093 Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO ...
Novel methods for preparation of Carfilzomib and intermediates thereof with high stereo selection are reported. The synthetic procedures result in...
2017/0298092 FINE FIBER WEB WITH CHEMICALLY FUNCTIONAL SPECIES
A functionalized fine fiber is provided. In an embodiment, the functionalized fine fiber is usable in chromatography. The functionalized fine fiber includes a...
2017/0298091 Mixed Bed Ion Exchange Adsorber
The present invention refers to new species of an ion exchange adsorber which is suitable for the separation of host cell proteins (HCPs), antibody fragments...
2017/0298090 Modulators of ROR-gamma Receptors, Composition and Use Thereof
The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ROR-gamma) in vitro and in vivo with...
2017/0298089 OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to...
2017/0298088 Vitamin E-Nucleoside Prodrugs
The present disclosure describes nucleoside and nucleoside analogues that are conjugated to a vitamin E derivative via a phosphate ester or a phosphoramidate...
2017/0298087 L-PROLINE COMPLEX OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, MONOHYDRATE AND CRYSTAL FORM THEREOF
Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically,...
2017/0298086 RNA INTERFERENCE AGENTS FOR P21 GENE MODULATION
This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules...
2017/0298085 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or...
2017/0298084 AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or...
2017/0298083 NEW IMMUNOSTIMULATORY COMPOUNDS
The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan Entamoeba histolytica. The compounds have...
2017/0298082 GLYCOSIDASE INHIBITORS
The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease ##STR00001## wherein A, R, W, Q, n, and m are...
2017/0298081 CONDENSED HETEROCYCLIC COMPOUND
A compound represented by the general formula (I) [R.sup.1 represents a C.sub.1-6 alkyl group, a halogen atom, or the like; A represents a phenylene group, or...
2017/0298080 AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed are aminosulfonyl-based compounds represented by the general formula I or tautomers, enantiomers, racemates or pharmaceutically acceptable salts...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.